Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?
Author:
- 1 June 2008
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (16) , 2616-2618
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal CancerJournal of Clinical Oncology, 2008
- The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to CarboplatinClinical Cancer Research, 2007
- ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivoMolecular Cancer Therapeutics, 2007
- An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian CancerJournal of Clinical Oncology, 2007
- Expression profiling and individualisation of treatment for ovarian cancerCurrent Opinion in Pharmacology, 2006
- Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessProceedings of the National Academy of Sciences, 2006
- Epothilones in the treatment of cancerExpert Opinion on Investigational Drugs, 2006
- Molecular profiling of platinum resistant ovarian cancerInternational Journal of Cancer, 2005
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Multidrug Resistance: Molecular Biology Clinical RelevanceJNCI: Journal of the National Cancer Institute, 1989